Newsroom.

(25 November 2025): In our 5Qs with… series in THRIVE, we speak with leaders across Australia’s life sciences sector — from CEOs and C-suite executives to key decision-makers — to hear their perspectives on the ecosystem and their vision for its future. 

(24 October 2025): AusBiotech is pleased to announce the re-election of Dr Marthe D’Ombrain, Head of Global Research Innovation at CSL, to its Board of Directors. Dr D’Ombrain brings more than two decades of leadership and experience spanning research, commercialisation, and innovation across the life sciences sector, both in Australia and internationally.

(24 October 2025): AusBiotech is delighted to announce the Queensland Government and Tourism and Events Queensland as the Host State Partners for the AusBiotech Invest and AusBiotech International Conference 2026 and 2027 — the premier events on the Asia-Pacific region's life sciences calendar.

(23 October 2025): AusBiotech, Australia’s peak industry body representing more than 3,000 life sciences members, has formalised a new partnership with the Taiwan Bio Industry Organization (Taiwan BIO), which represents Taiwan’s innovative life sciences and biotechnology sector and works to connect the Asian ecosystem globally to drive impactful innovation.

(23 October 2025): Australia’s biotechnology industry is gathering in record numbers at the annual AusBiotech International Conference, held in Melbourne this week.

(23 October 2025): AusBiotech, Australia’s peak body for the life sciences sector, is delighted to announce the appointment of Tamlyn O’Connor as their new Head of Global Trade and Partnerships. The role is part of the AusBiotech and the Australian Trade and Investment Commission (Austrade) TradeStart partnership, designed to accelerate the global growth of Australian life science companies.

(21 October 2025): Australia’s premier life sciences investment conference, AusBiotech Invest 2025, opens today, welcoming investors, innovators, and global partners to connect with some of Australia’s most investable biotechnology and medical technology companies. 

(14 October 2025):

AusBiotech is pleased to announce that the Hon Danny Pearson, Victorian Minister for Economic Growth and Jobs and Minister for Finance; the Hon Ros Spence, Victorian Minister for Agriculture, Community Sport, Carers and Volunteers; and Ms Michaela Settle, Parliamentary Secretary for Regional Victoria, will all speak at the flagship events of Australia’s biggest week in biotech — AusBiotech Invest and the AusBiotech International Conference 2025. 

(9 October 2025): AusBiotech welcomes the release of new guidance, Understanding Selection Criteria for Medical Device Application Audits, by the Therapeutic Goods Administration (TGA). Read more

(6 October 2025): AusBiotech has delivered is 2024-25 Annual Report outlining a pivotal year of renewal, growth, and strengthened national advocacy on behalf of Australia’s life science sector.

3 October 2025): AusBiotech welcomes the Albanese Government’s announcement of a $13.6 million investment to progress national health and medical research reforms and further strengthen Australia’s clinical trials ecosystem.

(2 October 2025): In the third quarter of 2025, AusBiotech has proudly welcomed a significant number of new members.

(1 October 2025): AusBiotech and Medicines Australia are inviting expressions of interest from current members to join the newly established Advanced Therapies Advisory Group, which will provide input into strategic leadership initiatives supporting Australia’s growing advanced therapies sector.

 

(25 September 2025): AusBiotech is delighted to announce that Senator the Hon Tim Ayres MP, Federal Minister for Industry and Innovation and Minister for Science, will join AusBiotech, the life sciences industry, international delegates and investors during Australia’s biggest week in biotech this October.

(5 September 2025): This September, AusBiotech will be celebrating Global Biotech Week (21–27 September), an international initiative designed to raise public and policymaker awareness of the biotechnology industry's importance and global potential. Together, these milestones shine a light on the people, organisations, and innovations driving better health outcomes in Australia and around the world. 

(29 August 2025): AusBiotech welcomes the Federal Government’s release of the draft National Health and Medical Research Strategy. Announced by the Hon Mark Butler MP, Minister for Health and Ageing, the 10-year plan will undergo further consultation before the final strategy is delivered by the end of 2025.

(20 August 2025): Last week, Australians came together to mark National Science Week — a celebration of the people and companies transforming discovery into innovations that improve lives.

(20 August 2025): AusBiotech was proud to partner with the Translational Research Institute (TRI) for a BioBriefing event where we welcomed Queensland’s Deputy Premier, the Hon Jarrod Bleijie MP, who announced the new name of the TRI’s Australia-first on-demand cGMP biomanufacturing facility: ENTRI. 

(20 August 2025): In our 5Qs with… series in THRIVE, we speak with leaders across Australia’s life sciences sector — from CEOs and C-suite executives to key decision-makers — to hear their perspectives on the ecosystem and their vision for its future. This edition features Dr Steve Burnell, Managing Director of Tenmile and Chair of its Investment Committee. 

(6 August 2025): In her powerful and future-focused maiden speech to Parliament, Senator Michelle Ananda-Rajah (VIC) laid out a vivid 40-year vision for Australia driven by science, technology and resilient communities. Among the most compelling messages was her call to harness the nation’s strengths in biotechnology — and transform it into a sovereign economic powerhouse.

(6 August 2025): Applications are now open for companies to pitch at AusBiotech Invest 2025 — Australia’s largest life sciences investment event, connecting innovators with capital to accelerate breakthroughs from research to commercialisation.

(31 July 2025): AusBiotech and Medicines Australia have marked the two-year conclusion of the joint venture Cell & Gene Catalyst by celebrating its outcomes and committing to greater industry collaboration to unify the industry’s efforts and voice.

(23 July 2025): At AusBiotech, we are proud to highlight Australian life sciences innovators through our Spotlight series — shining a light on local homegrown life sciences capabilities that reflect Australia’s broader vision for health innovation, commercialisation, and sovereign manufacturing. 

(23 July 2025): As we mark the midpoint of 2025, AusBiotech CEO Rebekah Cassidy reflects on our key achievements and the opportunities shaping the sector. 

(23 July 2025): AusBiotech is a member of the Regulatory and Technical Consultative Forum for medical devices (RegTech Forum). This forum, chaired by the TGA, meets quarterly and provides AusBiotech members a mechanism to raise regulatory or technical issues of concern, and identify opportunities to improve current regulatory practices.

(23 July 2025): National Science Week (9–17 August 2025) is Australia’s annual celebration of science and technology, recognising the research, discovery, and innovation shaping our world. This year’s theme — ‘Decoding the Universe: Exploring the unknown with nature’s hidden language’ — invites us to explore the fundamental building blocks of life and DNA, from quantum science and biology to data and diagnostics. 

(9 July 2025): The Albanese Government has signalled its intention to focus on boosting the nation’s sluggish productivity during this parliamentary term. Treasurer Jim Chalmers is kicking things off with an Economic Reform Roundtable at Parliament House in August.

(9 July 2025): The Albanese Government has signalled its intention to focus on boosting the nation’s sluggish productivity during this parliamentary term. Treasurer Jim Chalmers is kicking things off with an Economic Reform Roundtable at Parliament House in August.

(23 June 2025): AusBiotech, Australia’s peak body representing the innovative life sciences sector, has wrapped a significant week of bilateral and multilateral engagements at the BIO International Convention 2025 (BIO25) in Boston. 

(12 June 2025): AusBiotech and members of our MedTech Regulatory Affairs Advisory Group were pleased to participate in the RegTech Forum held at the Therapeutic Goods Administration (TGA) in Canberra on Thursday, 29 May. 

(4 June 2025): AusBiotech, Australia’s peak body for the life sciences sector, and the Australian Government's Trade and Investment Commission (Austrade) are partnering to accelerate the global growth and expansion of Australian life science companies.

(2 June 2025): AusBiotech welcomes the announcement of Australia’s federal Shadow Ministry and looks forward to the continued opportunity for engagement with the newly appointed team, as part of its ongoing commitment to supporting a strong, innovative life sciences sector. 

(28 May 2025): The Australian Government's Strategic Examination of Australia's Research and Development (SERD) system is set help grow core science and innovation capability. 

(28 May 2025): At AusBiotech’s flagship medical technology event, AusMedtech 2025, nearly 500 delegates gathered in Sydney to explore the future of healthcare and hear directly from some of Australia’s most influential leaders.

(14 May 2025): AusBiotech is pleased to support the next United Kingdom-Australia BioBridge event, taking place on 26 May 2025, which will bring together senior leaders from across the biotechnology, healthcare, and life sciences sectors.

(13 May 2025): AusBiotech welcomes the Albanese Government's announcement of its new cabinet and federal ministry. As the national peak body for Australia’s life sciences sector, AusBiotech congratulates all returning and newly appointed Ministers. We look forward to working in close partnership to strengthen Australia’s innovation-driven economy and advance life sciences as a national priority.

(7 May 2025): AusBiotech, Australia’s peak body for life sciences, welcomes the start of AusMedtech 2025, which starts today in Sydney, New South Wales (7–8 May 2025).

(6 May 2025): AusBiotech, Australia’s leading national industry body representing more than 3,000 life sciences members, has signed a partnership agreement with ANDHealth, the country’s premier provider of commercialisation support and services for the rapidly expanding digital and connected health sector. 

(6 May 2025): AusBiotech's Medtech Invest 2025, Australia’s premier medical technology investment conference, opens today in Sydney — kicking off a landmark week fostering meaningful connections, advancing collaboration, and driving growth in devices and diagnostics.

(5 May 2025): AusBiotech, Australia’s peak life sciences body, has officially launched its activation program as an Industry Partner Organisation under the Australian Government’s Industry Growth Program. Through this initiative, AusBiotech will deliver a range of activations designed to accelerate commercialisation and support the growth of chosen Industry Growth Program participants.

(30 April 2025): In the 2024-25 Federal Budget, the Australian Department of Industry, Science and Resources announced a strategic examination of Australia’s research and development (R&D) policies. 

(30 April 2025): In the first quarter of this year, AusBiotech proudly welcomed a significant number of new members. 

(22 April 2025): Recce Pharmaceuticals (ASX:RCE) has received Human Research Ethics Approval (HREC) to enrol up to 20 additional patients with Diabetic Foot Infections in its Phase 2 trial of R327G.

(17 April 2025): Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has announced the US FDA has granted PTX-100 a Fast Track Designation for the treatment of adults with relapsed or refractory mycosis fungoides, the most common subtype of Cutaneous T Cell Lymphoma.

(17 April 2025): Telix Pharmaceuticals (ASX:TLX) has announced that preliminary results from the Phase 2 IPAX-Linz study of TLX101 in recurrent high-grade glioma support the patient benefit seen in the IPAX-1 study.

(15 April 2025): Neuren Pharmaceuticals (ASX:NEU) has announced that the primary endpoints for its planned single Phase 3 pivotal clinical trial of NNZ-2591 in Phelan-McDermid syndrome have been confirmed at a Type C Meeting with the US FDA.

(15 April 2025): Noxopharm (ASX:NOX) has announced that its SOF-SKN lupus medication has passed its final in vivo preclinical safety study before regulatory submission for the upcoming HERACLES clinical trial.

(15 April 2025): Cell therapy immuno-oncology company Carina Biotech has reported a successful $5 million capital raise from existing and new shareholders.

(10 April 2025): Opthea (ASX:OPT) has updated investors following the recent termination of its COAST (Combination of OPT-302 with Aflibercept Study) and ShORe (Study of OPT-302 in combination with Ranibizumab) Phase 3 clinical trials.

(10 April 2025): Recce Pharmaceuticals (ASX:RCE) has announced a significant capital raise to support Phase 3 topical clinical trials in Indonesia and Australia.

(10 April 2025): Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced the appointment of Melanie Farris to the board as an independent non-executive director.

(10 April 2025): Researchers at the Walter and Eliza Hall Institute of Medical Research have shown that a new drug compound can prevent long COVID symptoms in mice.

(8 April 2025): The Baker Institute says the installation of next-generation proteomics and multi-omics technology this month will provide insights into cardiovascular biology, cell signalling and human health, supporting its researchers to accelerate the understanding of human cardiovascular health and disease.

(30 April 2025): AusBiotech is pleased to announce that the deadline to submit Expressions of Interest to join our influential NSW, QLD, SA, VIC, and WA State Committees has been extended to 16 May. 

(9 April 2025): AusBiotech has set out clear asks to all sides of politics ahead of the 2025 Federal Election on 3 May. It’s time for urgent action to ensure Australia’s thriving life sciences sector is recognised as a strategic national priority. 

(9 April 2025): We recently held our Engage for Impact event both in Sydney and online, designed to support members with the insights, skills, and networks needed to navigate Australia’s political landscape and build valuable connections for their organisations. 

(3 April 2025): Percheron Therapeutics (ASX:PER) has updated shareholders on its actions following the disappointing result in the Phase 2b trial of its avicursen in non-ambulant boys with Duchenne muscular dystrophy.

(1 April 2025): Opthea (ASX:OPT) has announced it will discontinue clinical trials involving its sozinibercept in combination with other therapies for treating wet age-related macular degeneration.

(27 March 2025): Neuren Pharmaceuticals (ASX:NEU) has initiated the development of NNZ-2591 to treat hypoxic-ischemic encephalopathy.

(27 March 2025): Amplia Therapeutics (ASX:ATX) has reported updated data from its ongoing Phase 2a ACCENT clinical trial investigating its FAK inhibitor narmafotinib in combination with standard-of-care chemotherapy in treating advanced pancreatic cancer.

(27 March 2025): AusBiotech, Australia’s peak life sciences body, has officially launched its activation program as an Industry Partner Organisation under the Australian Government’s Industry Growth Program. Through this initiative, AusBiotech will deliver a range of activations designed to accelerate commercialisation and support the growth of chosen Industry Growth Program participants.

(26 March 2025): While no new significant commitments were made for Australia’s life sciences sector in the 2025-26 Federal Budget, AusBiotech remains steadfast in its advocacy to unlock the full potential of this critical industry for Australia’s health, economic future, and security.  

(25 March 2025): Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that the US Patent and Trademark Office has allowed the issuance of a patent application covering the company's CHM CDH17 chimeric antigen receptor technology.

(25 March 2025): Noxopharm (ASX:NOX) has announced an expanded work program for 2025 with its strategic partner, Melbourne’s Hudson Institute of Medical Research.

(25 March 2025): Opthea (ASX:OPT) has reported negative outcomes from its pivotal Phase 3 clinical trial involving the combination of its sozinibercept with Bayer's EYLEA (aflibercept) for treating wet age-related macular degeneration.

(20 March 2025): Late-stage immunotherapy company Immutep (ASX:IMM) has announced an upcoming poster presentation for the pivotal TACTI-004 Phase 3 trial.

(20 March 2025): Australian clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced that the US FDA has granted Fast Track Designation to its allogeneic CAR T-cell therapy, azer-cel, for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

(20 March 2025): Since 2000, when it started in a makeshift basement laboratory, QBiotics has spent 25 years focused on discovering and developing novel cell signalling small molecules for challenging medical conditions.

(18 March 2025): OncoSil Medical (ASX:OSL) has announced the appointment of Shelley Steyn as chief financial officer, effective 5 May.

(18 March 2025): Nyrada (ASX:NYR) has commenced recruitment for its phase one clinical trial of its lead drug candidate NYR-BI03.

(18 March 2025): engagement with the US FDA on lifting the clinical hold on the company's investigational new drug application for NUZ-001.

(18 March 2025): Race Oncology (ASX:RAC) has announced that Bellberry has approved a phase one clinical trial of RC220 bisantrene alone and combined with doxorubicin in patients with solid tumours.

(13 March 2025): Telix Pharmaceuticals (ASX:TLX) has completed the transaction to expand its theranostic pipeline with new candidates targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nuclear medicine.

(13 March 2025): Proteomics International Laboratories (ASX:PIQ) has officially launched its first-in-class predictive test for diabetic kidney disease, PromarkerD, in Australia.

(13 March 2025): Australian biotechnology company Noxopharm (ASX:NOX) has engaged Doherty Clinical Trials to conduct its upcoming phase 1 HERACLES trial.

(11 March 2025): PolyNovo (ASX:PNV) has announced that its chief executive officer, Swami Raote, will officially leave the company in June but will step down immediately.

(11 March 2025): Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced that Dr James Campbell will succeed Steven Engle as its chair.

(7 March 2025): AusBiotech and Medicines Australia are partnering to deliver the annual Women in Life Sciences luncheon, bringing together 600 leaders from across the sector to celebrate the contribution of women in life sciences and call for accelerated action toward gender equity.  

(6 March 2025): "Through his leadership, BioMelbourne Network has solidified its position within the Victorian health technologies sector, delivering positive outcomes for members and stakeholders and contributing to the advancement of life sciences," said the organisation.

(6 March 2025): Clinical-stage biotechnology company Vaxxas has announced the publication of data supporting the potential use of its high-density microarray patch technology to deliver nucleic acid-based vaccines in collaboration with The University of Queensland and Technovalia.

(6 March 2025): A new report by Telix says the tens of thousands of Australians could miss out on a new era of cancer treatment without action from the government to secure the viability of the nuclear medicine sector, including enforcing regulatory standards.

(4 March 2025): CSL Seqirus has signed an agreement Esperion Therapeutics for the exclusive license and distribution agreement to commercialise NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Australia and New Zealand.

(4 March 2025): Avecho Biotechnology (ASX:AVE) and Sandoz have signed an exclusive ten-year development and licensing agreement for the commercial rights to the Australian company's phase 3 cannabidiol capsule for insomnia in Australia.

(4 March 2025): Clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of Darren Keamy as its chief financial officer and company secretary starting today.

(27 February 2025): Seventy-one experts from 54 organisations in Australia’s cell and gene ecosystem have been appointed to Cell and Gene Catalyst’s four expert working groups to action strategic projects that will benefit the industry.

(27 February 2025): Telix Pharmaceuticals (ASX:TLX) has announced that the US FDA has accepted its Biologics License Application for its breakthrough investigational kidney cancer PET imaging agent TLX250-CDx (Zircaix, 89ZrDFO-girentuximab).

(27 February 2025): Arovella Therapeutics (ASX:ALA) has announced that it has received firm commitments from institutional and sophisticated investors to raise approximately $15 million under a new placement.

(27 February 2025): Neuren Pharmaceuticals (ASX:NEU) has updated investors on the 2024 earnings announcement and conference call of its partner, Acadia Pharmaceuticals.

(27 February 2025): Clinical-stage regenerative medicine company Cambium Bio (ASX:CMB) has announced that the US FDA has approved the protocol for the registration-enabling Phase 3 clinical trials of Elate Ocular for the treatment of moderate to severe dry eye disease.

(25 February 2025): Regenerative medicine company Orthocell (ASX:OCC) has submitted an application to the Thai Food and Drug Administration for its leading nerve repair product, Remplir.

(25 February 2025): Neuren Pharmaceuticals (ASX:NEU) has received a Rare Paediatric Disease Designation from the US FDA for NNZ-2591 in Pitt-Hopkins syndrome and Angelman syndrome.

(25 February 2025): A new whitepaper from On Q Recruitment explores the key findings of its 2024 Salary & Job Market Report, highlighting how salary trends shape Australia’s life sciences industry.

(20 February 2025): Vaxxas has completed enrollment for its Phase 1 clinical trial of a vaccine against an avian influenza A (H7N9) virus with pandemic potential, delivered by the company’s proprietary high-density microarray patch.

(20 February 2025): The US FDA has granted fast-track designation for Neuren's NNZ-2591 for the treatment of Pitt Hopkins syndrome.

(20 February 2025): Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced that the US FDA has granted fast-track designation for 67Cu-SAR-bisPSMA for the treatment of adult patients with a form of prostate cancer.

(18 February 2025): Clinical-stage drug development company Syntara (ASX:SNT) has announced new findings from a subgroup analysis of 14 patients from the placebo-controlled SOLARIA2 trial.

(13 February 2025): AusBiotech welcomes the release of the Federal Government’s discussion paper on the Strategic Examination of R&D, underscoring the urgent need for reform to bolster Australia’s innovation ecosystem and global competitiveness. 

(11 February 2025): CEO and managing director Dr Paul McKenzie said, “CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in our core Ig franchise. We continue to advance key initiatives to improve gross margin, which is tracking according to our plans."

(11 February 2025): Australian clinical-stage radiopharmaceutical company AdvanCell has announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly to research and develop innovative cancer treatments.

(11 February 2025): PYC Therapeutics (ASX:PYC) has announced that it has received all required regulatory approvals to commence human clinical trials of PYC-003.

(6 February 2025): AdAlta (ASX:1AD) has announced it will accelerate its 'East to West' cellular immunotherapy growth strategy by executing two non-binding term sheets to in-license clinical-stage CAR-T products, bringing total products in advanced due diligence to three.

(6 February 2025): Clinical-stage company Vaxxas has announced the appointments of three respected vaccine experts as advisors to its product development and strategy team as it advances its novel high-density microarray patch (HD-MAP) vaccine technology towards later-stage clinical trials and commercialisation.

(4 February 2025): Argenica Therapeutics (ASX:AGN) has announced results from a more extensive preclinical study assessing the efficacy of ARG-007 in a rat model of moderate traumatic brain injury.

(4 February 2025): Noxopharm (ASX:NOX) has announced that its SOF-SKN lupus medication has successfully passed a set of important preclinical safety tests ahead of the upcoming HERACLES clinical trial.

(4 February 2025): AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, has successfully completed an oversubscribed US$112 million Series C financing.

(3 February 2025): In a pre-budget submission, AusBiotech and MTPConnect have called for new investment in strategic initiatives to boost Australia’s life sciences sector which is central to the nation’s productivity, health security and the health and wellbeing of all Australians.

(30 January 2025):  AusBiotech proudly celebrates the outstanding achievements of members recognised in this year's Australia Day Honours List. 

 These honours highlight the excellence and innovation at the heart of Australia's thriving life sciences sector and showcase its impact on science, public health, and global research.   

(28 January 2025): Telix Pharmaceuticals (ASX:TLX) has completed the acquisition of RLS (RLS Radiopharmacies), America’s only Joint Commission-accredited radiopharmacy network that distributes PET, SPECT, and therapeutic radiopharmaceuticals.

(28 January  2025): “I realised we had something special when our lead scientist on this programme came into my office and showed me some data related to the screening they'd been doing," said Dr Andrew Nash, CSL’s chief scientific officer.

(23 January 2025): Clinical-stage Australian biotechnology company Immutep (ASX:IMM) has completed enrolment in the investigator-initiated EFTISARC-NEO trial.

(21 January 2025): Neuren has announced that its partner Acadia has submitted a Marketing Authorisation Application to the EMAfor DAYBUE (trofinetide) for the treatment of Rett syndrome.

(21 January 2025): Vaxxas CEO David Hoey said, “We're honoured to have our world-leading microarray patch technology chosen to be part of this important BARDA-led public health initiative to accelerate new vaccine technologies."

(21 Jan 2025):  Global Contract Development and Manufacturing Organisations BioCina and NovaCina have announced a strategic merger to create a new biopharmaceutical and small molecule contract manufacturing brand.

(20 December 2024): Race Oncology (ASX:RAC) has announced the appointment of experienced biotechnology executive Dr Megan Baldwin to its board as an independent non-executive director.

(19 December 2024): The Catalyst continues to drive Australia’s cell and gene industry forward, fostering collaboration, amplifying the sector’s profile, and aligning advocacy efforts to achieve transformative outcomes.

(17 December 2024): Clinical-stage company Immutep (ASX:IMM) has announced new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 binds to its main ligand MHC Class II (MHC-II), also known as HLA Class II in humans.

(17 December 2024): Led by BioMelbourne Network, the new initiative brings together expertise from peak industry bodies and companies to create a voice and advocate on behalf of Victorian medtech manufacturers across the key issues impacting the sector.

(17 December 2024): AusBiotech invites member contributions for the April 2025 edition of the Australasian Biotechnology journal. 

 

(16 December 2024): AusBiotech, Australia’s leading national industry body representing more than 3,000 life sciences members, has formalised a new partnership with BioNSW, a rapidly growing not-for-profit organisation dedicated to harnessing the full potential of the New South Wales Life Sciences sector. The signing of this Memorandum of Understanding (MOU) represents a significant step forward in promoting a connected and thriving biotechnology ecosystem across NSW and beyond.

(12 December 2024): Neuren Pharmaceuticals (ASX: NEU) has announced that the sale of the Rare Pediatric Disease Priority Review Voucher by its partner Acadia Pharmaceuticals has been completed.

(12 December 2024): Immutep (ASX:IMM) has announced positive clinical results from Cohort B of the TACTI-003 (KEYNOTEC34) Phase 2b trial.

(12 December 2024): An immunotherapy that targets out-of-control viral infections has saved the lives of dozens of critically ill immunocompromised Australians who received the treatment on compassionate grounds.

(12 December 2024): Clinical-stage biotechnology company FivepHusion has announced a commercial transaction with the University of Wollongong for an exclusive option over its ResectAssist Drug Delivery Platform.

(11 December 2024): AusBiotech, Australia’s leading national industry association
representing more than 3000 members across the life sciences sector and BioMelbourne Network, Victoria’s leading industry association for organisations engaged in biotechnology, medical technology, and health innovation in Victoria have welcomed the release of Victoria’s Economic Growth Statement.

(10 December 2024): Recce Pharmaceuticals (ASX:RCE) has received approval from the Indonesian Drug and Food Regulatory Authority to initiate its registrational Phase 3 clinical trial, which will assess RECCE 327 as a topical gel for treating diabetic foot infections.

(10 December 2024): Clinical-stage biotechnology company FivepHusion has announced Human Regulatory Ethics Committee approval for the next clinical trial of Deflexifol to treat solid tumours.

(10 December 2024): Paradigm Biopharmaceuticals (ASX:PAR) has announced that it has received firm commitments for a capital raising totalling $16 million through a placement of fully paid ordinary shares to sophisticated and institutional investors.

(5 December 2024): Race Oncology (ASX:RAC) has announced the submission of the ethics and regulatory package to Bellberry Human Research Ethics Committee for approval of a Phase 1 clinical trial of RC220.

(5 December 2024):  Monash University and The Florey Institute of Neuroscience and Mental Health researchers were announced as joint winners at AusBiotech 2024's Early-Stage Innovation Forum (ESIF), at our annual conference in Melbourne.  

(4 December 2024): Regenerative medicine company Orthocell (ASX:OCC) has announced the successful completion of its Remplir 510(k) nerve repair study.

(2 December 2024): AusBiotech, Australia’s leading voice for life sciences, welcomes the Federal Government’s Strategic Examination of Research and Development (R&D) as an important step toward unlocking Australia’s innovation potential and driving economic growth.

(29 November 2024): Australia's leading advocate for life sciences, AusBiotech, today welcomes the appointment of Dr Dell Kingsford Smith to its Board of Directors.  

Dell joins the Board with more than 20 years of experience in clinical and commercial strategy across medical technology, pharmaceuticals, and vaccines. Her depth of expertise spans discovery to full commercialisation.  

(27 November 2024): On Tuesday, 19 November 2024, AusBiotech and MTPConnect jointly delivered Australia’s first National Biotech and Medtech Development and Commercialisation Summit in Canberra.

(26 November 2024): CEO and managing director Brent Barnes said, “With the growing sales momentum of APAS, we believe now is the ideal time to streamline and simplify communications with our customers and shareholders under the unified identity of Clever Culture Systems.”

(26 November 2024): Professor David Thomas said, “We are on the cusp of a new era in cancer care. It’s imperative to integrate this approach as mainstream care for all Australians.”

(26 November 2024): GE HealthCare and Peter MacCallum Cancer Centre have announced a partnership under which the Melbourne-based facility will evaluate a new positron emission tomography and computed tomography technology

(25 November 2024): AusBiotech welcomes the newly appointed members of the independent Health Technology Assessment (HTA) Reform Implementation Advisory Group. 

(21 November 2024): BioMelbourne Network is launching a one-year project to develop a central portal containing a workforce resource suite, thanks to the Victorian Government's support.

(21 November 2024): Race Oncology (ASX:RAC) says it has completed an FTO-targeted drug discovery program at Monash University’s Fragment Platform.

(19 November 2024): Melbourne-based company Neurizon Therapeutics has announced positive results from a preclinical study of its lead candidate, NUZ-001.

(19 November 2024): Australian company AdAlta (ASX:1AD) has announced the appointment of two new directors, including experienced industry executives Michelle Burke and Iain Ross.

(19 November 2024): Today’s National Biotech and Medtech Development and Commercialisation Summit 2024 in Canberra brings together more than 100 of Australia’s leading industry figures, policy experts, and innovators to shape the future of the nation’s biotech and medtech sectors with a unified voice.  

(14 November 2024): Clinical-stage company Immutep (ASX:IMM) has announced positive data from the investigator-initiated INSIGHT-003 Phase 1 trial evaluating its eftilagimod alpha in combination with MSD's KEYTRUDA (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer.

(14 November 2024): Amplia Therapeutics (ASX:ATX) has announced that it has entered into a research collaboration with Korean preclinical drug screening company Next&Bio.

(14 November 2024): AusBiotech is honoured to announce the establishment of the Depaz Oration, an annual keynote to be introduced at the AusBiotech Conference in 2025 in memory of the late Dr Iris Depaz.  

(7 November 2024): AusBiotech, Australia’s leading national industry body representing more than 3,000 life sciences members, and Life Sciences Western Australia, the leading body representing life sciences in Western Australia, have joined forces with a new Memorandum of Understanding (MOU) designed to help unlock growth opportunities through closer collaboration. This partnership aligns with a shared vision to elevate Australia’s position as a leader in biotechnology, medical technology, and health innovation on both state and national levels.

(7 November 2024): Neuren Pharmaceuticals (ASX:NEU) has announced that its partner Acadia Pharmaceuticals has entered into a definitive asset purchase agreement to sell the Rare Pediatric Disease Priority Review Voucher for US$150 million.

(7 November 2024):  AusBiotech and MTPConnect have released a Discussion Paper ahead of their upcoming National Biotech and Medtech Development and Commercialisation Summit, on 19 November 2024 in Canberra.

(5 November 2024): Recce Pharmaceuticals (ASX:RCE) says it is nearing completion of its Phase 2 clinical trial of RECCE 327 Topical Gel (R327G) targeting Acute Bacterial Skin and Skin Structure Infections.

(5 November 2024): Optiscan Imaging (ASX:OIL) has signed an agreement with Monash University to help the company advance its project to develop the next-gen gastrointestinal (GI) flexible endomicroscope and Edge-AI-enabled technology.

(5 November 2024): Imugene (ASX:IMU) has announced that a bile tract cancer patient in its Phase 1 MAST trial remains a complete response, now surpassing more than two years in remission. 

(31 October 2024): Australia’s biotechnology industry has gathered in record numbers at the annual AusBiotech conference, held in Melbourne this week.

The four-day conference, seen as one of the pre-eminent life sciences gatherings in the Asia Pacific region, has attracted a record-breaking 1600 attendees across the week, itself a record. More than 200 delegates have joined from overseas including major delegations from Korea and Tiawan.

(31 October 2024): AusBiotech and Life Sciences Queensland, the leading voice for Queensland’s biotechnology and health innovation sector, have signed a Memorandum of Understanding (MOU) to deepen collaboration and advance Australia’s life sciences industry.

(31 October 2024): Amplia Therapeutics (ASX:ATX) is undertaking a placement, director placement and entitlement offer to raise up to $13 million, with interim data from the ACCENT trial supporting its continuation.

(30 October 2024): AusBiotech and BioMelbourne Network, Victoria’s leading industry association for organisations engaged in biotechnology, medical technology, and health innovation, have signed a memorandum of understanding to promote stronger collaboration.

(30 October 2024): AusBiotech and the Korea Health Industry Development Institute (KHIDI) have signed a memorandum of understanding establishing a framework for collaboration and cooperation to support each country's growing biotechnology industries.

(29 Octoer 2024): Australia's premier life science investment event, AusBioInvest 2024, is in Melbourne today. It features industry-leading international speakers, keynote addresses from global investment leaders, and pitch presentations from top biotechnology companies.

(29 October 2024): Actinogen Medical (ASX:ACW) has announced the appointment of Andrew Udell, a US-based executive, as its chief commercial officer, reporting to CEO Dr Steven Gourlay.

(29 October 2024): "Published preclinical results show the potential immunogenic advantages of this antigen candidate as the basis for an RSV vaccine to provide robust and durable protection,” said Vaxxas CEO David Hoey.

(24 October 2024): Percheron Therapeutics (ASX:PER) will undertake a share purchase plan for eligible existing shareholders to allow them to participate in a recently announced institutional placement.

(24 October 2024): AdAlta (ASX:1AD) has announced an addition to its AdCella leadership team, with Dr Kevin Lynch appointed as consultant chief medical officer.

(24 October 2024): Kevin Richardson, CEO of Telix Precision Medicine, said, “Telix believes that the FDA approval of Pixclara will drive a step-change for brain cancer imaging in the US and bring it into line with a more advanced standard of care currently used in other markets."

(22 October 2024): Cell therapy company Chimeric Therapeutics (ASX:CHM) says it has received commitments for a two-tranche placement to sophisticated and professional investors to raise $5 million before costs.

(22 October 2024): AusBiotech is pleased to announce that Tim Pallas MP, the Victorian Minister for Economic Growth, and the Hon. Natalie Hutchins MP, the Victorian Minister for Jobs and Industry, will both speak at Australia’s biggest week in biotech – AusBioInvest and AusBiotech 2024. 

(21 October 2024): AusBiotech seeks to elect one new Board Director, and nominations are now open. As a member of AusBiotech, you are eligible to nominate for election. If you would like to make a greater contribution to AusBiotech and the Australian life sciences sector, we invite you to apply. 

(17 October 2024): CEO James Bonnar said, "We are thrilled to have completed the GLP studies, which have confirmed a favourable safety profile for NYR-BI03, giving us confidence that it will transition well into human studies."

(15 October 2024): Immuron (ASX:IMC) has announced the continued strong sales growth of Travelan, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract.

(15 October 2024): Respiri chairman Nicholas Smedley said, “The Board and I are pleased to welcome investors of this calibre onto our registry."

(14 October 2024): Advance Australia's thriving biotechnology and medtech sector; participate in the upcoming election as AusBiotech seeks to elect one new Board Director.

As Australia's leading national and global advocate for life sciences, AusBiotech is for its more than 3000 members, supporting their growth by building an Australian life sciences ecosystem that leads in development and commercialisation, creating high-quality, innovative life sciences companies.

(10 October 2024): Noxopharm (ASX:NOX) has contracted a specialist supplier to manufacture SOF-SKN for the upcoming HERACLES clinical trial.

(10 October 2024): Telix has announced that the TGA has approved the use of Illuccix to select patients for PSMA-targeted radionuclide therapy.

(10 October 2024): The CEO and managing director of Australian company Amplia Therapeutics (ASX:ATX), Dr Chris Burns, and Professor Andrew Wilks have shared the Prime Minister’s Prize for Innovation for their role in the discovery of JAK enzymes and their co-invention of the JAK inhibitor momelotinib.

(8 October 2024): Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that a patient with Acute Myelogenous Leukemia has recorded a complete response in its Phase 1b CHM CORE-NK and Vactosertib combination.

(8 October 2024): AusBiotech is delighted to announce that The Hon. Mark Butler MP, Federal Minister for Health and Aged Care, will join AusBiotech industry members, international delegates, and investors during Australia’s biggest week in biotechnology.

(3 October 2024): Life sciences financier Endpoints Capital has advanced pioneering Australian firm Vaxxas $9.7 million for its Research and Development Tax Incentive.

(3 October 2024): Nyrada (ASX:NYR) has announced positive results from a preclinical rat study evaluating the efficacy of its lead drug candidate, NYR-BI03, in coronary heart disease.

(1 October 2024): Cell therapy company Mesoblast (ASX:MSB) has entered into a convertible note subscription agreement with its largest shareholder, Gregory George, to issue up to US$50 million convertible notes at its discretion.

(1 October 2024): PolyNovo chairman David Williams said, “After 14 years Bruce has selflessly decided to stand aside to make way for new blood and concentrate on his other Board roles. He will be missed but I am confident he will still be available for his sage advice."

(1 October 2024): Percheron Therapeutics (ASX:PER) has announced the completion of a nine-month toxicology study in non-human primates for its lead program, avicursen.

(1 October 2024): Built by our members, to be the national voice of our sector we are proud to support our member's growth and leverage our national convening power to shape policy, foster knowledge sharing, and collaborate to advance life sciences in our country. Together, we work to help our members thrive.

(26 September 2024): Argenica Therapeutics (ASX:AGN) has announced the completion of crucial safety studies that are required to be included in its IND application.

(26 September 2024): Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced a partnership with US-based Achieve that aims to improve patient access to autologous cell therapies.

(26 September 2024): AusBiotech’s biotech and medtech members are being invited to complete the organisation’s first annual AusBiotech Voice on Investment Survey.

(25 September 2024)  To Members and other persons entitled to notice of Annual General Meetings (AGM) of AusBiotech Ltd, the 2024 AGM of AusBiotech Ltd will be held at the Melbourne Conference and Exhibition Centre and in accordance with the AusBiotech Constitution on Thursday 31 October 2024 at 12.30pm -1.30pm AEDT to transact the following business:

(24 September 2024): Immutep (ASX:IMM) has announced it has received a €2,194,918 (~A$3,6) research and development tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme

(24 September 2024): Telix Pharmaceuticals (ASX:TLX) has announced it will acquire America's only joint commission-accredited radiopharmacy network distributing PET1, SPECT2 and therapeutic radiopharmaceuticals.

(19 September 2024): AusBiotech and MTPConnect have announced a new partnership to deliver Australia’s first National Biotech and Medtech Development and Commercialisation Summit, to be held in Canberra on 19 November 2024.

(19 September 2024): Invion (ASX:IVX) has announced that RMW Cho Group, the licensor of the Photosoft technology, has completed a Phase 2 prostate cancer trial using a sublingual formulation of INV043.

(19 September 2024): Cochlear (ASX:COH) has announced that Sarah Thom will be its chief financial officer, effective 1 January 2025.

(17 September 2024): PharmAust (ASX:PAA) says it has completed a pre-submission meeting with the European Medicines Agency and the Committee for Orphan Medicinal Products and has submitted a request for orphan designation for monepantel for the treatment of amyotrophic lateral sclerosis.

(17 September 2024): Monash University researchers have discovered a blood cell that, when introduced to a bone, muscle, or skin injury, has the potential to promote rapid healing.
 

(17 September 2024): Immutep (ASX:IMM) has announced positive efficacy and safety results from the TACTI-003 Phase 2b trial evaluating its eftilagimod alpha in combination with MSD’s KEYTRUDA.

(17 September 2024): As the father of Australian biotech, Leon Serry AM is remembered for his pioneering work as an investor and philanthropist founding Cicardian (now Opthea Ltd), establishing the foundation of Australia’s biotech investment industry.

(12 September 2024): Thanks to a $10 million donation, Cabrini Health, in partnership with Monash University, is aiming to transform cancer care for Victorians.

(12 September 2024): Telix (ASX:TLX) has announced that the primary results from its Phase 3 ZIRCON trial have been published in The Lancet Oncology.

(12 September 2024): CUREator, Australia's national biotech incubator managed by Brandon BioCatalyst, has announced that four companies will receive top-up funding across its Preclinical and Health Security streams.

(12 September 2024): Vaxxas has initiated a multi-centre Phase 1 clinical trial of a vaccine against pre-pandemic avian influenza strain H7N9, using its high-density microarray patch.

(12 September 2024): The Federal Government has released the final report of the Health Technology Assessment (HTA) Review, marking the first comprehensive review of Australia’s HTA system in nearly 30 years.

(10 September 2024): Biotron (ASX:BIT) has provided an update on the BIT225-012 Phase 2 clinical trial of its lead antiviral drug BIT225 for treating COVID-19.

(10 September 2024): Nyrada (ASX:NYR) has provided an update on the development of its brain injury program with investigative first-in-class neuroprotection treatment, NYR-BI03.